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Background. The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in
patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim
of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein
subfractions in obese and lean nondiabetic individuals. Subjects and Methods. We enrolled ﬁfty nondiabetic obese patients and
thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis
factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked
immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry. Results.
The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be signiﬁcantly higher, while PON1
paraoxonase and arylesterase activities were nonsigniﬁcantly lower in the obese patients. Strong signiﬁcant negative correlations
were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of
the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by
waist circumference and intermediate HDL subfraction. Conclusion. The signiﬁcant correlations between PAI-1 levels and
lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.
1. Introduction
Excess adipose tissue in obesity is directly associated with
increased cardiovascular mortality and, in part, due to
comorbidities including hypertension, diabetes, and dyslip-
idemia [1, 2]. Low-grade inﬂammation and the procoagulant
milieu of obesity also contribute to increased cardiovascular
risk [3]. Plasminogen activator inhibitor-1 (PAI-1) is the pri-
mary regulator of ﬁbrinolysis breaking down ﬁbrin in the
intravascular compartment as well as breaking down the
extracellular matrix. PAI-1 also controls cell adhesion and
migration in the extravascular space and therefore may inﬂu-
ence the development of atherosclerotic plaque formation
[4–6]. Elevated PAI-1 concentration is an established risk
factor for coronary artery disease [7, 8].
Increased levels of PAI-1 in obese subjects with metabolic
syndrome and in type 2 diabetic patients are well docu-
mented [9–11]. Furthermore, a direct association was
observed between PAI-1 level and waist circumference in
healthy subjects [12]. In another study, values of BMI
and PAI-1 correlated signiﬁcantly in obese and overweight
subjects [13]. The association between PAI-1 and obesity
is considered to be the result of increased PAI-1 produc-
tion of adipose tissue by various cell types including
preadipocytes, mature adipocytes, macrophages, endothe-
lial and smooth muscle cells [14, 15]. It is generally
accepted that visceral or ectopic adipose tissue produces
more PAI-1 than does subcutaneous adipose tissue [16].
Visceral adipose tissue secretes higher amount of proin-
ﬂammatory cytokines, such as TNF-α, TGF-β1, IL-6, and
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IL-1, and also contains more stromal cells and macrophages,
which are the main cellular components of adipose tissue
that produce PAI-1 [17, 18].
Plasma lipoproteins represent heterogeneous popula-
tions with respect to their size, density, electrophoretic
mobility, and lipid and protein composition [19]. Low-
density lipoprotein (LDL) particles transport lipid molecules
into peripheral tissues, for example, into the arterial wall.
Predominance of the small-dense LDL subspecies results in
increased susceptibility to oxidative modiﬁcations and
subsequently enhanced atherosclerosis and increased cardio-
vascular risk [20]. In turn, high-density lipoprotein (HDL)
particles are generally considered to be protective against
atherosclerosis, as the large-sized HDL subfractions are
primarily ascribed to reverse cholesterol transport [21], while
the small-sized HDL subfractions rather exert antioxidant
eﬀects through their associated anti-inﬂammatory enzyme
termed paraoxonase-1 (PON1). Myeloperoxidase (MPO) is
a leukocyte-derived heme protein bound to HDL and is
linked to enhanced oxidative stress and atherosclerosis.
Recent data indicate that MPO, PON1, and HDL may bind
and inhibit each other, forming a ternary complex [22].
In epidemiological studies, direct associations were
observed between PAI-1 and lipid parameters (e.g., triglycer-
ide and HDL-C levels) in healthy young adults [12]. Also,
recent studies postulated that very low density lipoprotein
(VLDL) was capable of increasing the PAI-1 level through a
VLDL response element localized to the promoter region of
the PAI-1 gene, mediating VLDL-induced PAI-1 transcrip-
tion in endothelial cells [23, 24]. A previous in vitro study
also showed that small-sized HDL, but not large-sized
HDL, stimulated PAI-1 release in the murine 3T3 adipocyte
cell line [25]; however, to date, there are limited data on the
association of PAI-1 with the functional and structural prop-
erties of the diﬀerent lipoprotein fractions. Therefore, the
aim of the present study was to examine the relationship
between plasma PAI-1 levels and the distributions of HDL
and LDL subfractions as well as to conﬁrm the potential asso-
ciations between the concentrations of PAI-1 and the HDL-
linked enzymes PON1 and MPO, respectively, in obese and
lean nondiabetic patients.
2. Patients and Methods
2.1. Study Population. We enrolled ﬁfty nondiabetic obese
patients that were referred to our obesity outpatient clinic
at the Division of Metabolic Diseases, Department of
Medicine, University of Debrecen, Hungary, and thirty-two
sex- and age-matched healthy volunteers. All participants
provided written informed consent. The study protocol was
approved by the Local Ethical Committee of University of
Debrecen, and the study was carried out in accordance
with the Declaration of Helsinki. Obesity was deﬁned as B
MI ≥ 30 kg/m2, while the BMI of the control subjects was
normal (between 18.5 and 29.9 kg/m2). Participants with
active liver, endocrine (including any types of diabetes
mellitus), cardiovascular, pulmonary, neurological, gastroin-
testinal, psychiatric, acute infective, or autoimmune disease;
renal impairment; or malignancy were excluded. Further
exclusion criteria were pregnancy, lactation, current
smoking, and alcoholism or drug dependence. Neither obese
subjects nor nonobese healthy controls were taking lipid-
lowering, hyperglycemic, anti-inﬂammatory, and antithrom-
botic medications or dietary supplements and any drug,
which may interfere with the measurements. None of the
participants were on antihypertensive treatment with the
exception of ten obese patients, who were on diuretics
(indapamide) because of mild hypertension.
2.2. Sample Collection and Laboratory Measurements. All
venous blood samples were collected after a 12-hour fasting.
The routine laboratory parameters were measured by the
Central Laboratory of the University of Debrecen. The
measured parameters were the following: fasting glucose,
fructosamine, high-sensitivity C-reactive protein (hsCRP),
total cholesterol, triglyceride, HDL cholesterol (HDL-C),
LDL cholesterol (LDL-C), apolipoprotein AI (apoAI), apoli-
poprotein B (apoB), and lipoprotein(a). To check the carbo-
hydrate metabolism of the study participants, we applied a
routine 75 g oral glucose tolerance test (OGTT) after an
overnight fast. At the same time, hemoglobin A1c (HbA1c)
and fasting insulin were also measured. Homeostasis model
assessment-insulin resistance (HOMA-IR) was calculated
with the formula of Matthews et al. [25]. Serum and EDTA
plasma samples were kept frozen at −70°C for enzyme-
linked immunosorbent assay (ELISA) measurements and
for subsequent lipoprotein subfraction analysis. In our work,
we followed the methods of Szentpéteri et al. [26].
2.3. Lipoprotein Subfraction Analyses. HDL subfractions
were analyzed by a polyacrylamide gel-electrophoresis with
the Lipoprint System (Quantimetrix Corp., CA, USA)
according to the manufacturer’s instructions as previously
published [27].
Brieﬂy, 25μl serum of samples was added to the poly-
acrylamide gel tubes along with 300μl lipophilic Sudan
Black containing a loading gel solution and was photopo-
lymerized at room temperature (20–22°C) for 30min.
Tubes were performed by electrophoresis at a constant of
3mA/tube for 50min. Each electrophoresis chamber
involved a standard-quality control provided by the manu-
facturer (Liposure Serum Lipoprotein Control, Quantimetrix
Corp., CA, USA). After electrophoresis, stained subfractions
were scanned with an ArtixScan M1 digital scanner
(Microtek International Inc., CA, USA) and were identi-
ﬁed by their mobility (Rf) using VLDL+LDL as the
starting (Rf 0.0) reference point and albumin as the ending
(Rf 1.0) reference point.
Between the starting and ending reference points, 10
HDL subfraction bands were determined and were collected
into three major classes: large (HDL1–HDL3), intermediate
(HDL4–HDL7), and small (HDL8–HDL10) HDL subfrac-
tions. Cholesterol concentrations of the HDL particles were
calculated with Lipoware software (Quantimetrix Corp.,
CA, USA) by multiplying the total HDL-C concentration of
the samples by the relative area under the curve (AUC%) of
the subfraction bands.
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LDL subfractions were also detected using Lipoprint Sys-
tem (Quantimetrix Corp., CA, USA) [26] according to the
instructions of the manufacturer. 25μl sera were added to
polyacrylamide gel tubes along with 200μl Sudan Black con-
taining a loading gel solution. The sample loading gel mix-
ture was photopolymerized for 30minutes at 20–22°C prior
to electrophoresis at a constant of 3mA/tube for 60min.
LDL subfractions were identiﬁed after electrophoresis by
their mobility (Rf) using VLDL as the reference point (Rf 0.0)
and HDL as the ending reference point (Rf 1.0). AUC% for
the VLDL, midbands A, B, and C (comprising primarily
IDL), up to seven LDL subfractions and HDL peaks were
calculated by Lipoware computer software (Quantimetrix
Corp., CA, USA). Percentage of large LDL (large LDL%)
was deﬁned as the sum of the percentage of LDL1 and
LDL2, whereas percentage of small LDL (small-dense
LDL%) was deﬁned as the sum of LDL3–LDL7. Cholesterol
concentrations of LDL subfractions were determined by
multiplying the relative AUC of subfractions by the total cho-
lesterol concentration of the sample. Calculated total LDL-C
is comprised of the sum of the cholesterol in midbands (A, B,
and C) and LDL subfractions (LDL1–LDL7) and strongly
correlates with the directly measured LDL-C [28, 29]. Mean
LDL size was calculated by Lipoware software.
2.4. Determination of Human Paraoxonase-1 Enzyme
Activities. Serum PON1 arylesterase activity was measured
with phenylacetate substrate (Sigma Aldrich, Hungary), and
the hydrolysis of phenylacetate was monitored at 270nm at
room temperature as previously described [30, 31]. Serum
PON1 paraoxonase activity was assayed on a microtiter plate
by a kinetic, semiautomated method using paraoxon (O,O-
diethyl-O-p-nitrophenyl phosphate, Sigma-Aldrich, Hun-
gary) as a substrate. Hydrolysis of paraoxon was followed at
405nm at room temperature.
2.5. ELISA Measurements. Human plasma serpin E1/PAI-1,
TNF-α, IL-6, and MPO concentrations were measured by a
commercially available ELISA kit (R&D Systems, Minneapo-
lis, MN, USA) according to the manufacturer’s instructions.
The intra- and interassay coeﬃcients of variations were
3.1–8.7% and 7.2–10.4% (TNF-α), 6.9–7.8% and 6.5–9.6%
(IL-6), and 6.6–7.7% and 6.5–9.4% (MPO), respectively.
Oxidized LDL levels were detected by ELISA (Mercodia AB,
Sweden) with 5.5–7.3 CV% intra-assay precision and 4–6.2
CV% inter-assay precision, respectively, according to the
recommendations of the manufacturers.
2.6. Statistical Methods. Statistical analysis was performed by
STATISTICA software, version 8.0 (StatSoft Inc., Tulsa, OK,
USA). Data were presented by descriptive analysis (means
± SD in the case of normal distribution, or medians [lower
quartile–upper quartile] in the case of nonnormal distribu-
tion). The Kolmogorov-Smirnov test was used for testing
the normality of data distribution. Comparisons between
groups were performed by Student’s unpaired t-test in the
case of normally distributed variables and by the Mann–
Whitney U test in the case of variables with nonnormal dis-
tribution. Correlations between continuous variables were
assessed by linear regression analysis using Pearson’s test.
Since the distribution of some variables of interest became
normal upon base-10 logarithm transformation, we used
in the case of these variables the log values for correlation
analyses. Multiple regression analysis was performed to
determine the variables’ best-predicted PAI-1 concentra-
tions. Results were considered to be signiﬁcant at the level
of p < 0 05.
3. Results
Anthropometric and laboratory characteristics of study par-
ticipants are summarized in Table 1. Obese patients had
extremely high BMI (p < 0 001) and slightly elevated hsCRP
level (p < 0 001), compared to lean individuals. Although
there were several other diﬀerences in the laboratory
parameters in nondiabetic obese patients compared to lean
controls, these data were found to be in the physiological
range. Plasma triglyceride and lipoprotein(a) concentra-
tions were measured to be signiﬁcantly higher, while the
levels of HDL-C and apoAI were signiﬁcantly lower in the
obese group, compared to normal-weight controls. Regard-
ing the carbohydrate parameters, the HbA1c level was sig-
niﬁcantly higher, but within the normal range in the
obese individuals. Fasting glucose was in the normal range
in both groups, and blood glucose level at 120min of
OGTT was not elevated in the obese group. The obese
patients involved into this study had neither diabetes nor
abnormal glucose tolerance on the basis of glucose concen-
trations during OGTT.
Levels of the inﬂammatory markers TNF-α and IL-6 were
signiﬁcantly higher (p < 0 01 and p < 0 001, resp.) in nondia-
betic obese patients compared to lean individuals (Table 1).
Additionally, the levels of oxidized LDL and MPO were
found to be signiﬁcantly higher (p < 0 01 and p < 0 05, resp.),
while PON1 paraoxonase and arylesterase activities were
nonsigniﬁcantly lower in the obese patients.
Absolute amounts of lipoprotein subfractions are shown
in Table 2. The concentration of the VLDL subfraction was
measured to be higher (p < 0 001), while IDL levels were
lower in the obese patients compared to controls (p < 0 001).
Levels of large and small-dense LDL subfractions were
increased in the patient group, but not in the lean participants
(p < 0 01 and p < 0 001, resp.). Mean LDL size was signiﬁ-
cantly lower in the obese subjects (p < 0 001). Although
HDL-C levels fell into the normal range in both studied
groups, there was a shift towards the small-sized HDL parti-
cles in nondiabetic obese individuals. The concentrations of
the large and intermediate HDL subfractions were found to
be signiﬁcantly decreased (p < 0 001 and p < 0 05, resp.),
while small HDL subfraction levels were signiﬁcantly
increased in the obese patients compared to the normal-
weight individuals (p < 0 01) (Table 2).
The median level of PAI-1 was also signiﬁcantly higher in
obese patients compared to lean participants (obese: 6.58 [5–
8.58] versus control: 2.93 [1.8–5.23] ng/ml; p < 0 001)
(Figure 1). We were unable to detect gender diﬀerences
between females and males neither in the obese (p = 0 458)
nor in the control group (p = 0 314), respectively. Pearson
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Table 1: Anthropometric and routine laboratory parameters of the study participants.
Obese (n = 50) Control (n = 32) p
Gender (F/M) 43/7 27/5 ns
Age (yr) 44.20± 13.50 41.78± 5.97 ns
Body mass index (kg/m2) 41.96± 8.63 24.47± 2.51 <0.001
Waist circumference (cm) 119.76± 16.87 83.62± 9.25 <0.001
hsCRP (mg/l) 8.24 (3.2–13.09) 1.57 (0.6–2.94) <0.001
Fructosamine (μmol/l) 225.32± 27.95 229.0± 11.65 ns
Thyroid stimulating hormone (mU/l) 1.98± 0.98 1.93± 1.15 ns
Lipid parameters
Triglyceride (mmol/l) 1.4 (1.1–2.0) 1.0 (0.75–1.39) <0.01
Total cholesterol (mmol/l) 5.04± 0.83 5.07± 0.78 ns
HDL cholesterol (mmol/l) 1.36± 0.33 1.56± 0.46 <0.05
LDL cholesterol (mmol/l) 3.17± 0.74 2.93± 0.52 ns
Apolipoprotein A–I (g/l) 1.48± 0.24 1.68± 0.31 <0.01
Apolipoprotein B (g/l) 0.86± 0.20 0.94± 0.18 ns
Lipoprotein(a) (mg/l) 248 (120–586) 70 (30–214) <0.001
Carbohydrate parameters
Hemoglobin A1C (%) 5.76± 0.54 5.07± 0.33 <0.001
Fasting glucose (mmol/l) 4.90± 0.75 4.82± 0.48 ns
OGTT 120min 7.00± 2.01
Fasting insulin (mU/l) 21.01± 15.91
HOMA-IR 3.75 (2.4–6.52)
Inﬂammatory and oxidative markers
Tumor necrosis factor-α (pg/ml) 1.783 (1.41–2.254) 1.39 (1.20–1.67) <0.01
Interleukin-6 (pg/ml) 3.439 (1.817–4.89) 0.97 (0.63–1.28) <0.001
Oxidized LDL (U/l) 46.8± 9.95 41.1± 9.57 <0.01
Paraoxonase activity (U/l) 64.72 (43.79–149.52) 83.03 (47.9–167.4) ns
Arylesterase activity (U/l) 121.61± 23.65 131.1± 28.75 ns
Myeloperoxidase (ng/ml) 280 (148.3–386.3) 207.9 (125.8–265.2) <0.05
Values are presented as mean ± standard deviation or median (lower quartile–upper quartile). HDL: high-density lipoprotein; hsCRP: high-sensitivity
C-reactive protein; LDL: low-density-lipoprotein; OGTT: oral glucose tolerance test; HOMA-IR: homeostasis model assessment-insulin resistance;
ns: nonsigniﬁcant.
Table 2: Concentrations of lipoprotein subfractions in nondiabetic obese and lean participants.
Obese (n = 50) Control (n = 32) p
VLDL subfraction (mmol/l) 1.165± 0.17 0.868± 0.17 <0.001
Midband (IDL) (mmol/l) 1.207± 0.31 1.505± 0.38 <0.001
LDL subfractions
Large LDL (mmol/l) 1.267 (1.06–1.603) 1.047 (0.827–1.344) <0.01
Small-dense LDL (mmol/l) 0.091 (0.026–0.155) 0.026 (0–0.052) <0.001
Mean LDL size (nm) 26.98± 0.31 27.26± 0.37 <0.001
HDL subfractions
Large HDL (mmol/l) 0.284 (0.207–0.388) 0.453 (0.31–0.608) <0.001
Intermediate HDL (mmol/l) 0.6594 (0.595–0.828) 0.749 (0.659–0.853) <0.05
Small HDL (mmol/l) 0.336 (0.284–0.388) 0.284 (0.246–0.336) <0.01
Values are presented as mean ± standard deviation or median (lower quartile–upper quartile).
4 International Journal of Endocrinology
correlations of PAI-1 concentrations with the lipid parame-
ters of the study participants are summarized in Table 3.
BMI, waist circumference, triglyceride, VLDL subfraction,
large LDL subfraction, and small-dense LDL subfraction
showed positive associations with PAI-1 levels, while there
was an inverse correlation between the concentrations of
the IDL subfraction and PAI-1, as well as between mean
LDL size and PAI-1 level. Plasma PAI-1 concentrations cor-
related negatively with total HDL-C and apoA1 levels,
respectively, in the whole study population (Table 3;
Figures 2(a) and 2(b)). We also found a strong inverse corre-
lation between plasma PAI-1 levels and the concentrations of
large and intermediate HDL subfractions, respectively
(Table 3; Figures 2(c) and 2(d)).
Furthermore, plasma PAI-1 levels showed positive corre-
lations with hsCRP, IL-6, and TNF-α levels in the study par-
ticipants, whereas oxidized LDL and MPO concentrations, as
well as PON1 paraoxonase and arylesterase activities, did not
show associations with plasma PAI-1 levels (Table 3).
To test whether the associations detected in univariate
analyses were independent of lipid parameters, we carried
out a multiple regression analysis with PAI-1 level as the
dependent variable. Besides age, gender, BMI, and waist cir-
cumference, the model included large HDL, intermediate
HDL, small HDL, large LDL, and small-dense LDL subfrac-
tion concentrations and mean LDL size. Based on the back-
ward stepwise analysis, the PAI-1 level turned out to be
best predicted by waist circumference and intermediate
HDL subfraction concentration (Table 4).
4. Discussion
To the best of our knowledge, this is the ﬁrst report about the
correlations between plasma PAI-1 levels and lipoprotein
subfractions in vivo, indicating the potential role of disturbed
lipid metabolism in PAI-1 overproduction in obesity. Levels
of other inﬂammatory markers (CRP, IL-6, TNF-α, oxLDL,
and MPO) were increased in the obese nondiabetic group
as well, while HDL-bound antioxidant enzyme activities
(PON1 paraoxonase and arylesterase) were nonsigniﬁcantly
lower, compared to the lean controls.
In line with a previous study [32], higher levels of VLDL
subfractions were found in the obese patients while the LDL-
C levels did not diﬀer signiﬁcantly between the obese and
control groups. Lipoprotein subfraction analysis showed a
decreased mean LDL size and higher amounts of large and
small-dense LDL subfractions contributing to the predomi-
nance of the atherogenic lipid proﬁle in obesity [20]. While
epidemiological studies reported decreased HDL-C concen-
trations in obese patients, the atherogenic properties of the
various HDL subfractions are contradictory because of their
functional and structural heterogeneity [33]. Previous studies
also indicated that decreased amount of large HDL particles
and increased amount of small HDL particles were closely
and signiﬁcantly associated with increased cardiovascular
risk [21]. However, a prospective study performed on type
2 diabetes patients reported that the level of large-sized, but
not the small-sized HDL subfraction predicted a lower risk
of cardiovascular disease [34]. In our obese nondiabetic
group, the HDL-C concentration was in normal range but
it was signiﬁcantly lower compared to the lean controls.
Additionally, HDL subfraction analysis showed higher con-
centrations of small HDL and lower levels of intermediate-
and large-HDL subfractions in the obese nondiabetic group
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Figure 1: Plasma concentrations of plasminogen activator
inhibitor-1 (PAI-1) in nondiabetic obese and lean participants
(obese: 6.58 [5–8.58] and control: 2.93 [1.8–5.23] ng/ml; p < 0 001).
Table 3: Linear regression analyses of log10 PAI-1 in all study
participants.
Variable r p
Age 0.098 0.38
Body mass index 0.578 <0.001
Waist circumference 0.579 <0.001
Lipid parameters
Log10 triglyceride 0.421 <0.001
Total cholesterol −0.167 0.14
VLDL subfraction 0.284 0.01
Midband (IDL) subfraction −0.482 <0.001
LDL-C 0.074 0.51
Apolipoprotein B −0.078 0.51
Log10 large LDL subfraction 0.382 <0.001
Log10 small-dense LDL subfraction 0.315 0.01
Mean LDL size −0.447 <0.001
HDL-C −0.5 <0.001
Apolipoprotein AI −0.426 <0.001
Log10 large HDL subfraction −0.569 <0.001
Log10 intermediate HDL subfraction −0.523 <0.001
Log10 small HDL subfraction 0.177 0.11
Inﬂammatory markers
Log10 hsCRP 0.444 <0.001
Log10 interleukin-6 0.485 <0.001
Log10 tumor necrosis factor-α 0.223 <0.05
Oxidative stress markers
Oxidized LDL 0.171 0.13
Log10 PON1 paraoxonase activity −0.157 0.16
PON1 arylesterase activity −0.194 0.09
Log10 myeloperoxidase 0.129 0.26
HDL: high-density lipoprotein; hsCRP: high-sensitivity C-reactive protein;
LDL: low-density lipoprotein; PON1: paraoxonase-1.
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compared to the lean controls. The observed diﬀerences in
the distribution of the lipoprotein subfractions may
highlight the importance of the early screening of obese
individuals to predict the development of subsequent
cardiovascular complications.
The link between increased circulating PAI-1 level and
metabolic syndrome is not completely clariﬁed. PAI-1
concentration was found to be strongly associated with the
components of metabolic syndrome (degree of obesity,
elevated triglyceride level, decreased HDL level, and insulin
resistance) [35]; however, other studies did not ﬁnd an
association between plasma PAI-1 level and dyslipidemia
[36, 37]. These ﬁndings suggest that plasma PAI-1 concen-
tration is rather determined by the phenotypic distribution
of the adipocytes, but it is not closely dependent on total fat
mass. Indeed, plasma PAI-1 is mostly considered as a marker
of ectopic fat deposition [16] and although both BMI and
waist circumference showed signiﬁcant pairwise correlations
with PAI-1 level in our study, only the waist circumference
remained the predictor of PAI-1 level among anthropometric
parameters during the multivariate analysis.
There are many mediators that may play a signiﬁcant role
in the interaction between PAI-1 and the traits of metabolic
syndrome. Correlations between TNF-α and TGF-β
pathways and PAI-1 in adipose tissue are well documented
[38, 39]. Dexamethasone and cortisol are potent inducers of
PAI-1 synthesis in cultured adipocytes; therefore, cortisol
may also be an inducer of PAI-1 in visceral obesity [40].
Hypertriglyceridemia and VLDL also induce PAI-1 synthesis
through a VLDL response element localized in the promoter
region of the PAI-1 gene [23]. Since we did not investigate
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Figure 2: Correlations between plasminogen activator inhibitor-1 (PAI-1) and (a) high-density lipoprotein cholesterol (HDL-C), (b)
apolipoprotein AI (apoAI), (c) large HDL subfraction, and (d) intermediate HDL subfraction in nondiabetic obese (●) and normal-weight
controls (Δ).
Table 4: Multivariate analysis in all study participants for PAI-1 as a
dependent variable.
Variable Beta p value
Age 0.025 ns
Gender 0.254 ns
BMI −0.26 ns
Waist circumference 0.342 <0.001
Log10 large HDL −0.02 ns
Log10 intermediate HDL −0.52 <0.001
Log10 small HDL 0.093 ns
Log10 large LDL −0.03 ns
Log10 small-dense LDL −0.09 ns
Mean LDL size −0.15 ns
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these associations, we cannot state whether such mechanisms
exist in nondiabetic obese individuals in vivo.
We could ﬁnd gender diﬀerences in PAI-1 level neither of
obese nor of lean subjects. The gender diﬀerence of plasma
PAI-1 level is controversial. Margaglione and coworkers
found elevated PAI-1 level in males in a general population.
The male sex was an independent variable determining
PAI-1 level in multiple stepwise regression analysis [41].
van Harmelen et al. have found two times higher plasma
PAI-1 activity in males, which was mainly due to gender dif-
ferences in the waist-hip ratio. [42]. Mantovani et al. reported
gender diﬀerences in PAI-1 levels of adolescents. In normal-
weight males, PAI-1 levels were signiﬁcantly lower than those
of the females [43]. Based on our backward stepwise analysis,
the PAI-1 level was not predicted by gender (Table 4).
Corroborating previous ﬁndings, a signiﬁcant positive
correlation was detected between PAI-1 and triglyceride
levels, while PAI-1 and HDL-C showed a negative correlation
in nondiabetic obese patients and lean controls. Additionally,
we demonstrated a strong, signiﬁcant negative correlation
between mean LDL size and plasma PAI-1 concentration.
Furthermore, we detected a signiﬁcant positive correlation
between the most atherogenic, small-dense LDL subfraction
concentration and plasma PAI-1 level. The negative correla-
tion between plasma PAI-1 level and LDL size was described
by Festa et al. in a nondiabetic population, while this associ-
ation was weaker both in patients with impaired glucose
tolerance and in diabetic ones [44]. Additionally, a positive
association was found between the levels of plasma PAI-1
and small-dense LDL in healthy middle-aged men [45]. This
is the ﬁrst work, however, to evaluate the correlations
between LDL size/small-dense LDL levels and plasma PAI-
1 concentrations in obese nondiabetic patients. These data
support the suggested link between LDL and PAI-1 in
accelerated atherogenesis and increased cardiovascular risk
of obese patients; however, our hypothesis needs to be veri-
ﬁed in further investigations.
The levels of large- and intermediate-HDL subfraction
showed negative associations with the circulating PAI-1
levels, but no correlation was found between the PAI-1 level
and the concentration of small HDL subfraction in the whole
cohort. Based on the multivariate analysis, waist circumfer-
ence and intermediate HDL subfraction are the independent
predictors of plasma PAI-1 level; however, the link between
HDL subfractions and plasma PAI-1 level is not well under-
stood. Using sequential ultracentrifugation, Lee et al. showed
that HDL3-, but not HDL2-bound sphingosine-1-phosphate,
stimulates PAI-1 secretion in a concentration-dependent
manner in 3T3 adipocytes. In our study, we could not ﬁnd
a signiﬁcant correlation between PAI-1 and small-HDL sub-
fraction concentration (which mostly corresponds to HDL3)
using nongradient gel electrophoresis for lipoprotein sub-
fraction analysis. Still, based on the in vitro results,
sphingosine-1-phosphate may have a potential role in ele-
vated plasma PAI-1 level in obese nondiabetic patients [46].
Further studies need to clarify the link between PAI-1 pro-
duction and sphingosine-1-phosphate in obese patients.
We are aware of some limitations of this study. The rela-
tively small size of the study population and the small
number of the enrolled males may reduce the power of our
study; however, the signiﬁcant correlations between PAI-1
levels and lipoprotein subfractions underline the association
between PAI-1 and lipid metabolism. Beside quantitative
measurement of lipoprotein subfractions using Lipoprint,
determination of qualitative properties of lipoproteins, that
is, cholesterol eﬄux capacity, may provide more detailed data
about impaired lipoprotein function in obesity. Moreover, a
more precise assessment of visceral and ectopic fat mass
(MRI or PET scan) should be also helpful for the evaluation
of the association between PAI-1 level and the amount of
fat storage.
5. Conclusion
In conclusion, we found a strong signiﬁcant negative correla-
tion in obese and lean subjects between plasma PAI-1
concentration and the levels of large- and intermediate-
HDL subfractions. Mean LDL size showed a negative correla-
tion with plasma PAI-1 concentration. On the basis of
multiple regression analysis, waist circumference and
intermediate-HDL subfraction were predictors of plasma
PAI-1 concentration. In contrast with earlier reports, the
above correlations underline the relationship between PAI-
1 and lipoprotein metabolism in obesity. Further studies on
obese patients with diabetes or coronary heart disease might
also add valuable information about the relationship of
PAI-1 and obesity-related lipid abnormalities.
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